DelveInsight’s ‘Type 1 Diabetes Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline type 1 diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the type 1 diabetes pipeline domain.

 

Key Takeaways from the Type 1 Diabetes Pipeline Report

• DelveInsight’s type 1 diabetes pipeline report depicts a robust space with 80+ companies working to develop 100+ pipeline therapies for type 1 diabetes treatment.
• Key type 1 diabetes companies such as Landos Biopharma, Zealand Pharma,  Prevention Bio, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Novartis, ImCyse, , Tolerion, Avotres, REMD Biotherapeutics, Novo Nordisk, Eledon Pharmaceuticals, Avotres, Eli Lilly and Company, GEROPHARM, Regeneron Pharmaceuticals, Diamyd Medical, NextCell Pharma, Novartis, ViaCyte, Op-T LLC, Dompe Farmaceutici, ILTOO Pharma, Throne Biotechnologies, Oramed, Adocia, Imcyse, Janssen Biotech, Xeris Pharmaceuticals, Zealand Pharma, Jaguar Gene Therapy,  SQZ Biotech, Enthera, and others are evaluating new type 1 diabetes drugs to improve the treatment landscape.
• Promising type 1 diabetes pipeline therapies in various stages of development include LABP 111, TTP 399, Teplizumab, Emricasan, VX 880,  Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine, ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin, Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301,  Dasiglucagon, SQZ TAC research program, Ent001, and others.
• In July 2022, Vertex Pharmaceuticals announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash.
• In June 2022, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemia awareness and severe hypoglycemia.

• In April 2022, AVM Biotechnology received Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D). The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.
• In May 2022, Sernova and Evotec are pleased to announce an exclusive global strategic partnership to develop a best-in-class cell therapy treatment for people living with insulin-dependent diabetes. The partnership provides Sernova a global exclusive option to license Evotec’s iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15M and will make a further investment of €5M.
• In March 2022, Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes (T1D), have invested in the company.
• In January 2022, Remedium Bio announced it has entered into a Sponsored Research Agreement with the University of Massachusetts Boston to complete pre-clinical efficacy studies on Type 1 and Type 2 Diabetes pipeline candidates. The collaboration to evaluate platform technology for the treatment of Diabetes, with translational potential to the broader Remedium pipeline of single-injection potentially disease-modifying gene therapies.

 

 

Request a sample and discover the recent advances in type 1 diabetes treatment drugs @ Type 1 Diabetes Clinical trial Outlook

 

The type 1 diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage type 1 diabetes products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the type 1 diabetes pipeline landscape.

 

Type 1 Diabetes Overview

Type 1 diabetes mellitus (T1DM) is an autoimmune disease that causes the loss of insulin-producing pancreatic beta cells. Insulin is a necessary anabolic hormone that influences glucose, lipid, protein, and mineral metabolism, as well as growth. The exact type 1 diabetes causes are unknown. T1DM develops in three phases. Stage 1 is asymptomatic and is distinguished by normal fasting glucose, normal glucose tolerance, and the presence of more than or equivalent to two pancreatic autoantibodies.

Type 1 diabetes symptoms might occur unexpectedly and include frequent urine, weight loss, blurry vision, tiredness, weakness, and others. The blood test is the most common method for type 1 diabetes diagnosis.

 

Find out more about type 1 diabetes treatment drugs @ Type 1 Diabetes Medications 

 

A snapshot of the Type 1 Diabetes Pipeline Drugs mentioned in the report:

Drugs	Company
Teplizumab	Prevention Bio
Dasiglucagon	Zealand Pharma
AT-1501	Eledon Pharmaceuticals
AVT001	Avotres
IMCY-0098	ImCyse
Iscalimab	Novartis
Emricasan	Histogen
VX-880	Vertex Pharmaceuticals
NNC0363 0845	Novo Nordisk
Eflornithine	Panbela Therapeutics
LABP 111	Landos Biopharma

 

Learn more about the novel and emerging type 1 diabetes pipeline therapies @ Type 1 Diabetes Clinical Trials

 

Type 1 Diabetes Therapeutics Assessment

The type 1 diabetes pipeline report proffers an integral view of the type 1 diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Type 1 Diabetes Pipeline Report 

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intravenous, Oral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Cell therapy, Peptide, Small molecule, Polymer, Gene therapy
• Therapeutics Assessment By Mechanism of Action: CD3 antigen inhibitors, Apoptosis inhibitors, Caspase inhibitors, Pancreatic beta cell replacements, Glucagon receptor agonists, LANCL2 protein stimulants, Ornithine decarboxylase stimulants, Immunostimulants and Cytotoxic T lymphocyte stimulants,
• Key Type 1 Diabetes Pipeline Therapies:  LABP 111, TTP 399, Teplizumab, Emricasan, VX 880,  Encapsulated islet cell program, Eflornithine oral, Iscalimab, IMCY 0098, AT-1501, TOL 3021, AVT001, Volagidemab, NNC0363 0845, NNC0268-0965, LY 3209590, GP40071, Autoimmune diabetes vaccine , ProTrans, MHS 552, VC-02, OPT101, VC-01, Ladarixin, Aldesleukin , Stem Cell Educator therapy, ORMD-0801, ADO09, IMCY-0098, Glucagon intranasal, Golimumab, LY 900027, PRAM9JAG301,  Dasiglucagon, SQZ TAC research program, Ent001 and others

 

Dive deep into rich insights for new drugs for type 1 diabetes treatment, visit @ FDA-approved Type 1 Diabetes Drugs

 

Table of Contents

1.	Type 1 Diabetes Pipeline Report Introduction
2.	Type 1 Diabetes Pipeline Report Executive Summary
3.	Type 1 Diabetes Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Type 1 Diabetes Pipeline Therapeutics
6.	Type 1 Diabetes Pipeline: Late Stage Products (Pre-registration)
7.	Teplizumab: Prevention Bio
8.	Type 1 Diabetes Pipeline: Late Stage Products (Phase III)
9.	Dasiglucagon: Zealand Pharma
10.	Type 1 Diabetes Pipeline: Mid Stage Products (Phase II)
11.	IMCY-0098: ImCyse
12	Type 1 Diabetes Pipeline: Early Stage Products (Phase I)
13.	NNC0363 0845: Novo Nordisk
14.	Type 1 Diabetes Pipeline Therapeutics Assessment
15.	Inactive Products in the Type 1 Diabetes Pipeline
16.	Company-University Collaborations (Licensing/Partnering) Analysis
17.	Key Companies
18.	Key Products in the Type 1 Diabetes Pipeline
19.	Unmet Needs
20.	Market Drivers and Barriers
21.	Future Perspectives and Conclusion
22.	Analyst Views
23.	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight